Osteoclasts directly influence castration-resistant prostate cancer cellsVisa övriga samt affilieringar
2022 (Engelska)Ingår i: Clinical and Experimental Metastasis, ISSN 0262-0898, E-ISSN 1573-7276, Vol. 39, nr 5, s. 801-814Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Metastasis to bone is the leading cause of death from prostate cancer. Interaction between tumor cells and bone cells can promote progression and influence tumor phenotype. It is known that prostate cancer cells support osteoclast differentiation, and degradation of bone matrix by osteoclasts releases growth factors stimulating tumor cell proliferation and invasion. In the present study osteolytic (PC-3) and osteoblastic (LNCaP-19) castration-resistant prostate cancer (CRPC) cells were co-cultured with mature osteoclasts or their precursor cells (RAW 264.7) to characterize direct effects of mature osteoclasts on CRPC cells. Osteoclasts increased proliferation and decrease apoptosis of CRPC cells as assessed with flow cytometry. RNA sequencing revealed that osteolytic CRPC cells were more responsive to osteoclast stimulation regarding gene expression, but the overall induced expression patterns were similar between the prostate cancer cell lines. Genes related to DNA repair were upregulated by osteoclasts, while genes related to endoplasmic reticulum stress-induced apoptosis and cholesterol synthesis were downregulated. The results of this study shows that osteoclasts directly influence CRPC cells, increasing proliferation, decreasing apoptosis, and affecting gene expression pathways that can affect sensitivity to DNA damage and endoplasmic reticulum function. This suggests targeting of osteoclasts to be a possible way to affect efficacy of other drugs by combination regimens in treating prostate cancer metastases.
Ort, förlag, år, upplaga, sidor
Springer Nature, 2022. Vol. 39, nr 5, s. 801-814
Nyckelord [en]
Apoptosis, Castration-resistant prostate cancer, DNA repair, Osteoclasts, RNA sequencing
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-202711DOI: 10.1007/s10585-022-10179-2ISI: 000840609500001PubMedID: 35971022Scopus ID: 2-s2.0-85136155604OAI: oai:DiVA.org:umu-202711DiVA, id: diva2:1726440
Forskningsfinansiär
Cancerfonden, CAN 2017/478Cancerfonden, CAN 2017/380Cancerfonden, 20 1055Knut och Alice Wallenbergs Stiftelse2023-01-132023-01-132023-01-17Bibliografiskt granskad